Zacks Analyst Blog highlights key biotech stocks and their recent updates

Moderna’s been in the spotlight, sharing their sales forecasts for 2024 and 2025. They’re expecting around $3 billion from COVID-19 vaccine sales, but they had to lower their 2025 revenue guidance by a billion bucks. Ouch!
Then there’s Intellia, which had a rough week after announcing some strategic changes and job cuts. They’re focusing on a new gene-editing candidate but it seems investors weren’t too thrilled about the news.
Regeneron also had some updates, reporting impressive sales for their Eylea drug and filing for new FDA approvals. They’re really pushing to expand their pipeline, which is exciting.
Sage Therapeutics is getting attention too, as Biogen made a move to acquire them, offering a nice premium on their stock price. And GSK is on the acquisition trail, planning to buy IDRx, a biotech firm working on treatments for tumors.
Overall, it’s a busy time in biotech, and these companies are making some big moves. Keep an eye on them!